title: Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010.
abstract: Chronic myeloid leukemia (CML) has paradigm shift in its treatment modality after the discovery of targeted therapy Imatinib. At our centre we collected data of 100 consecutive patients over a period of 8 years. The interesting finding in our study was difference in the survival of patients presenting in early chronic phase (81%) versus late chronic phase (16%). Also the patients with primary resistance did poorly compared to the patients who developed secondary resistance to Imatinib.
authors: Department of Medical Oncology, Asian Institute of Oncology, S. L. Raheja Hospital, Mahim, Mumbai, Maharashtra, India.
authors: Shweta
authors: S
authors: Bansal
authors: Department of Medical Oncology, Asian Institute of Oncology, S. L. Raheja Hospital, Mahim, Mumbai, Maharashtra, India.
authors: S H
authors: SH
authors: Advani
keywords: Chronic myeloid leukemia; Glivec; chronic phase; veenat